Liver Disease Research Center for Biological Therapy, Beijing 302 Hospital, Beijing, China.
Cell Mol Immunol. 2011 Jan;8(1):19-22. doi: 10.1038/cmi.2010.57. Epub 2010 Nov 22.
Transplantation of mesenchymal stem cells (MSCs) has been recently studied in animal models, and in clinical trials of patients with fulminant hepatic failure, end-stage liver diseases and inherited metabolic disorders. Modulatory cytokines produced by MSCs can inhibit immunocyte proliferation and migration to the liver, thereby attenuating inflammatory injury and reducing hepatocyte apoptosis. In addition, MSCs play an important role in regressing liver fibrosis and in supporting the function, proliferation and differentiation of endogenous hepatocytes under appropriate conditions. Although remarkable progress has been achieved in basic and clinical MSC studies, optimal therapeutic regimens for the clinical application of MSCs, such as optimal doses, transplantation routine and interval period for transplantation, need to be elucidated in detail. Furthermore, the long-term safety and therapeutic efficacy of MSC transplantation should be evaluated in future clinical trials. This review summarizes our current understanding of the immunomodulatory effects of MSC therapies on human liver diseases.
间充质干细胞（MSCs）移植最近在动物模型中得到了研究，并在暴发性肝衰竭、终末期肝病和遗传性代谢紊乱患者的临床试验中进行了研究。MSCs 产生的调节细胞因子可以抑制免疫细胞向肝脏的增殖和迁移，从而减轻炎症损伤和减少肝细胞凋亡。此外，MSCs 在肝纤维化消退和在适当条件下支持内源性肝细胞的功能、增殖和分化方面发挥着重要作用。尽管在 MSC 的基础和临床研究中取得了显著进展，但仍需要详细阐明 MSC 临床应用的最佳治疗方案，如最佳剂量、移植常规和移植间隔期。此外，在未来的临床试验中应评估 MSC 移植的长期安全性和治疗效果。本综述总结了我们目前对 MSCs 疗法对人类肝脏疾病的免疫调节作用的认识。
